FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Haviland Kate					2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC]								all app Direct Office	ionship of Reportin all applicable) Director Officer (give title		10% Ov				
(Last)	`	irst) (MEDICINES CC	∕iiddle) RPOI	RATION	3. Date of Earliest Transaction (Month/Day/Year) 03/04/2021							Λ	below	,	below) erating Officer					
45 SIDN	EY STRE	ET			1 If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							-	6. Individual or Joint/Group Filing (Check Applicable						
(Street)	IDGE M	[A 0	2139		7.117	America	ment,	Date	or Origin	iai i iii	su (wonaveu	yr reary		Line)	Form	filed by One	e Rep	orting Pers	on	
(City)	(S	tate) (Z	Zip)												1 0100					
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quired	l, Dis	sposed of	, or B	enefic	cially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/				Execution Date,			3. Transaction Code (Instr. 8)		Acquire (D) (Ins	ed (A) or tr. 3, 4 a	nd 5) Securit Benefic		ties Fo cially (D) d Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price	Trar		action(s) 3 and 4)			(Instr. 4)	
Common Stock 03/04/20)21			S ⁽¹⁾		124	D	\$89.)9 ⁽²⁾ 5		55,776		D				
Common Stock 03/04/20)21			S ⁽¹⁾		1,828	D	\$86	.61	53,948			D				
		Tal	ole II								osed of, convertib				Owned	k				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	Price of ivative curity str. 5)	tive derivative ty Securities	Owners Form: Direct (I or Indire (I) (Instr	Ownership	Beneficial Ownership tt (Instr. 4)				
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$88.99 to \$89.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

/s/ Christopher Frankenfield, Attorney-in-Fact

03/05/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.